COMPARISON OF 68Ga-PSMA PET-CT WITH CONVENTIONAL IMAGING IN LOCALIZATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER
Conclusions: PSMA imaging detected unknown sites of disease in more than half of patients with BCR prostate cancer in this cohort. All positive findings on conventional imaging were also positive on PSMA imaging.
Conclusions: In this study, the cost of care during 2012-2016 was substantially higher for mCRPC than nmCRPC, underscoring the value of interventions that may delay progression to metastases in high-risk individuals. PMID: 31589086 [PubMed - as supplied by publisher]
ConclusionThis study confirmed that enzalutamide plasma concentrations were not related to PSA ‐independent PFS, TTPP, or toxicity in patients with mCRPC, and demonstrated that plasma concentrations of its major metabolites were also not associated with treatment response. Based on these findings, there is no role for therapeutic drug monitoring of enzalutamide in patients with mCRPC in dai ly practice.
ConclusionsSeviteronel demonstrates linear PK over the dose range of 50 –750 mg given either BID or QD in men with advanced CRPC or men and women with breast cancer. The disposition of seviteronel following oral administration is well described by this population PK model and can be used for accurate simulations for future studies with body weight and sex affecting c learance, but not to a clinically-meaningful degree requiring a change in the current dosing scheme.
ConclusionsDarolutamide has a low potential for clinically relevant DDIs with drugs that are substrates for CYP or P-gp; increased exposure of BCRP and probably OATP substrates was the main interaction of note.
Authors: Chen D, Fan N, Mo J, Wang W, Wang R, Chen Y, Hu J, Wen Z Abstract Background: Patients with esophageal cancer (EC) frequently have multiple primary cancers. We conducted the present study to assess the risk of multiple primary malignancies for patients with squamous cell carcinoma (SCC) and adenocarcinoma (AC) of the esophagus and to investigate the influence of multiple primary tumors on the prognosis of EC patients. Methods: Using the data of 44,091 EC patients from the Surveillance Epidemiology and End Results (SEER) database, we calculated the standardized incidence ratios (SIRs) for overall multip...
Results from the second interim analysis of the Phase 3 SPARTAN study featured in an oral presentation at ESMO 2019 and simultaneously published in Annals of Oncology
Bayer data at ESMO 2019 highlights innovation in cancer researchNew data for larotrectinib on durability of response in patients with TRK fusion cancer to be presented in a poster discussion on September 28 / Data from Bayer's prostate cancer franchise to be presented, including clinical relevance of drug-drug interactions in men with nmCRPC taking darolutamide and real-world data and pain evalutation data in men with mCRPC treated with radium-223 dichloride / New analyses from the Phase II study REGOBONE evaluating the efficacy and safety of regorafenib in patients with rare locally advanced or metastatic relapsed chondro...
This study examined whether glyburide altered Ca2+ signaling and viability in PC3 human prostate cancer cells and investigated those underlying mechanisms. Intracellular Ca2+ concentrations ([Ca2+ ]i ) in suspended cells were measured by using the fluorescent Ca2+ -sensitive dye fura-2. Cell viability was examined by WST-1 assay. Glyburide at concentrations of 100-1000 μM induced [Ca2+ ]i rises. Ca2+ removal reduced the signal by approximately 60%. In Ca2+ -containing medium, glyburide-induced Ca2+ entry was inhibited by 60% by protein kinase C (PKC) activator (phorbol 12-myristate 13 acetate, PMA) and inhibitor (GF1092...
ConclusionIn conclusion, a bioequivalent lower dose of abiraterone taken with food could not be established in our study. Although based on the absence of a exposure –toxicity relationship, the strict bioequivalence margins as defined by the FDA guidelines could be applied more flexible for abiraterone. Information on the effect of food on abiraterone pharmacokinetics as presented in our study can be used for patients with difficulties taken their medication f asted.
Conclusion.Combining cediranib with docetaxel + prednisone failed to demonstrate superior efficacy, compared with docetaxel + prednisone, and added toxicity. Our data do not support pursuing the combination further in patients with mCRPC.